This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bermudez, L. E.
Right arrow Articles by Young, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bermudez, L. E.
Right arrow Articles by Young, L. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2685-2687, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2685-2687.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Thiosemicarbazole (Thiacetazone-Like) Compound with Activity against Mycobacterium avium in Mice

Luiz E. Bermudez,1,2* Robert Reynolds,3 Peter Kolonoski,1 Pricilla Aralar,4 Clark B. Inderlied,4,5 and Lowell S. Young1

Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, California 94115,1 Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon 97331,2 Southern Research Institute, Birmingham, Alabama,3 Children's Hospital of Los Angeles,4 University of Southern California, Los Angeles, California5

Received 10 March 2003/ Returned for modification 3 April 2003/ Accepted 14 May 2003

In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 µg/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.

* Corresponding author. Mailing address: Department of Biomedical Sciences, College of Veterinary Medicine, 106 Dryden Hall, Oregon State University, Corvallis, OR 97331-4804. Phone: (541) 737-6532. Fax: (541) 737-8035. E-mail: luiz.bermudez{at}oregonstate.edu.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2685-2687, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2685-2687.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dover, L. G., Alahari, A., Gratraud, P., Gomes, J. M., Bhowruth, V., Reynolds, R. C., Besra, G. S., Kremer, L. (2007). EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets. Antimicrob. Agents Chemother. 51: 1055-1063 [Abstract] [Full Text]  
  • Bermudez, L. E., Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., Young, L. S. (2004). SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease. Antimicrob. Agents Chemother. 48: 3556-3558 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»